-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OhZc0fIwse/Z3Gbsy1vSvOG/TBziseMCy4AcM+J3dJ3qVAkTWy9TRpCQFuK1Xb9T
 t079MvLvDZ3RED1FmH1duA==

<SEC-DOCUMENT>0001021408-02-002595.txt : 20020414
<SEC-HEADER>0001021408-02-002595.hdr.sgml : 20020414
ACCESSION NUMBER:		0001021408-02-002595
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20020219
ITEM INFORMATION:		Other events
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20020219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SERVICES, NEC [8900]
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23386
		FILM NUMBER:		02553350

	BUSINESS ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
		BUSINESS PHONE:		7277230333

	MAIL ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG. B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.txt
<DESCRIPTION>FORM 8-K
<TEXT>
<PAGE>

                      SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of
                      the Securities Exchange Act of 1934


       Date of Report (Date of earliest event reported) February 19, 2002
                                                        -----------------


                        Commission File Number 000-23386
                                                  ------


                         CRYO-CELL INTERNATIONAL, INC.
                         -----------------------------
                 (Name of Small Business Issuer in its charter)


          DELAWARE                              22-3023093
          -------------                         ------------------
          (State or other jurisdiction          (I.R.S. Employer
          of incorporation or                   Identification No.)
          organization)


          3165 McMullen Booth Road, Building B, Clearwater, FL  33761
   ------------------------------------------------------------------------
            (Address of Principal Executive Offices)     (Zip Code)


          Issuer's phone number, including area code: (727) 450-8000

          ___________________________________________________________
         (Former name or former address, if changed since last report)
<PAGE>

Item 5.  Other Events

Incorporated by reference is a press release issued by the Registrant on
February 19, 2002, attached as Exhibit 99, concerning the Registrant's
announcement of the newly appointed President and Chief Operating Officer, John
V. Hargiss.


Item 7. Financial Statements and Exhibits

(c)  Exhibits

Exhibit 99      Press release issued February 19, 2002. Filed with this document
<PAGE>

                                   SIGNATURES


        Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                      CRYO-CELL INTERNATIONAL, INC.


Date:  February 19, 2002              By: /s/ Daniel D. Richard
                                          ____________________________
                                          Daniel D. Richard
                                          Chief Executive Officer
<PAGE>

                                 EXHIBIT INDEX


Exhibit
Number         Description
- ------         -----------

  99           Press Release Issued February 19, 2002

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>dex99.txt
<DESCRIPTION>PRESS RELEASE ISSUED 2/19/2002
<TEXT>
<PAGE>

                                                                      EXHIBIT 99

                 [LETTERHEAD OF CRYO-CELL INTERNATIONAL, INC.]


For Immediate Release       Contact:  Jill Taymans
                                      727-723-0333
                                      727-723-0444 (Fax)
                                      investor.relations@cryo-cell.com

     CRYO-CELL NAMES JOHN V. HARGISS PRESIDENT AND CHIEF OPERATING OFFICER
     ----------------------------------------------------------------------

Clearwater, FL - February 19, 2002 - Daniel D. Richard, Chairman and CEO of
CRYO-CELL International, Inc. (NASDAQ- C C E L) announced today that its Board
of Directors has named John V. Hargiss to the position of President and Chief
Operating Officer. Mr. Hargiss was selected from an extensive search of hundreds
of candidates, and assumed his new responsibilities on February 18. Mr. Richard
commented. "I am pleased to have John Hargiss fill this critical position at
this particular juncture. Mr. Hargiss and I share similar philosophies for
marketing, organization structure and cost containment. With the relevant
industry experience that he brings to the Company, we will be well positioned to
accelerate our current growth and significantly scale up the business to take
full advantage of the many market opportunities before us".

Mr. Hargiss has over 25 years of senior management and public company experience
within the medical device, biomedical, and healthcare services industries.
Prior to joining CRYO-CELL, he was a health care consultant, providing advisory
services to firms within the biotechnology, medical device, and heath care
services segments.  Mr. Hargiss served as President, Chief Executive Officer of
Biodynamics, International, Inc., (currently Tutogen Medical, Inc., AMEX: TTG)
for nine years.  The company is a publicly traded biomedical concern with
operations in the U.S. and Germany, and is engaged in tissue
processing/preservation and the development of autologous blood processing
technology.  Prior to this, he served as Corporate Vice President of Sales and
Marketing for the $200 million health care services unit of the BOC Group, plc
(NYSE:  BOX).  Mr. Hargiss held several executive management positions during
his twelve-year career with Becton-Dickinson & Co. (NYSE:  BDX), a multi-
national medical and laboratory product firm.  Mr. Hargiss holds an M.B.A. from
the University of Miami (FL) and a B.S. from the University of Texas.

Mr. Hargiss stated, "I look forward with great enthusiasm to joining the CRYO-
CELL management team and working closely with its founder and visionary, Dan
Richard.  CRYO-CELL has assembled the key resources necessary to realize the
full potential of this emerging global enterprise within the rapidly expanding
field of ethical stem cell processing and preservation".  He continued, "With
its proprietary cryo-preservation technology, its solid reputation among its
expanding client base, and its strong balance sheet, CRYO-CELL is poised to
solidify its position of industry leadership.

CRYO-CELL is now the world's largest and fastest growing U-Cord stem cell
banking firm, offering affordable cord blood storage exclusively for the benefit
of newborn babies and possibly other members of their family.  The Company has
also become the largest exclusive computerized, robotically operated U-Cord stem
cell repository.  CRYO-CELL has pioneered America's most affordable U-Cord
preservation program.

CRYO-CELL is a publicly traded company.  NASDAQ Symbol ... C C E L.

Forward Looking Statement

     Statements wherein the terms "believes", "intends", "projects" or "expects"
as used are intended to reflect "forward looking statements" of the Company. The
information contained herein is subject to various risks, uncertainties and
other factors that could cause actual results to differ materially from the
results anticipated in such forward looking statements or paragraphs. Readers
should carefully review the risk factors described in other documents the
Company files from time to time with the Securities and Exchange Commission,
including the most recent Annual Report on Form 10-K, Quarterly Reports on Form
10-Q and any Current Reports on Form 8-K filed by the Company.

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
